Somatostatin receptor PET ligands - the next generation for clinical practice.

ABSTRACT: Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be exploited for molecular imaging and for peptide receptor radionuclide therapy. ¹¹¹In-DTPA-octreotide has long been the standard in SSTR scintigraphy. A major leap forward was the introduction of gallium-68 labeled SSAs for positron emission tomography (PET) offering improved sensitivity. Tracers currently in clinical use are ⁶⁸Ga-DOTA-Tyr³-octreotide (⁶⁸Ga-DOTATOC), ⁶⁸Ga-DOTA-Tyr³-octreotate (⁶⁸Ga-DOTATATE) and ⁶⁸Ga-DOTA-1-NaI³-octreotide (⁶⁸Ga-DOTANOC), collectively referred to as ⁶⁸Ga-DOTA-peptid

SUBMITTER: Pauwels E 

PROVIDER: S-EPMC6261874 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature